Skip to main content
Erschienen in: Endocrine 1/2013

01.02.2013 | Review

1,5-Anhydroglucitol in diabetes mellitus

verfasst von: Won Jun Kim, Cheol-Young Park

Erschienen in: Endocrine | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

The measure of glycated hemoglobin (HbA1c) concentration is the gold standard of glycemic control index in diabetes management and is well known as a marker for diabetes complications. However, HbA1c level neither accurately reflect glucose fluctuations, nor does it provide a clear indication of glycemic control in recent days or weeks. HbA1c concentration measurement can be confounded in patients with anemia, hemoglobinopathy, liver disease, or renal impairment. 1,5-Anhydroglucitol (1,5-AG) structurally resembles glucose. It can be influenced by diet or medication, gender and race, especially severe renal disease and various pathological conditions. Most notably, 1,5-AG level is reflective of short-term glucose status, postprandial hyperglycemia, and glycemic variability which are not captured by HbA1c assay. 1,5-AG may suggest an alternative index of subtypes of diabetes and a warning sign of diabetes complications. This review provides an overview of our current understanding of the role of 1,5-AG marker in diabetes. However, further investigations on the associations between this glycemic marker and diabetes complications are needed.
Literatur
1.
Zurück zum Zitat The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993)CrossRef The Diabetes Control and Complications Trial Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993)CrossRef
2.
Zurück zum Zitat UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998)CrossRef UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352, 837–853 (1998)CrossRef
3.
Zurück zum Zitat American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 33, S62–S69 (2011)CrossRef American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 33, S62–S69 (2011)CrossRef
4.
Zurück zum Zitat K.M. Dungan, 1,5-Anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev. Mol. Diagn. 8, 9–19 (2008)PubMedCrossRef K.M. Dungan, 1,5-Anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions. Expert Rev. Mol. Diagn. 8, 9–19 (2008)PubMedCrossRef
5.
Zurück zum Zitat T. Yamanouchi, Y. Akanuma, Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res. Clin. Pract. 24(Suppl), S261–S268 (1994)PubMedCrossRef T. Yamanouchi, Y. Akanuma, Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res. Clin. Pract. 24(Suppl), S261–S268 (1994)PubMedCrossRef
6.
Zurück zum Zitat M. Koga, S. Kasayama, Clinical usefulness of glycated albumin as an another glycemic control marker. Endocr. J. 57, 751–762 (2010)PubMedCrossRef M. Koga, S. Kasayama, Clinical usefulness of glycated albumin as an another glycemic control marker. Endocr. J. 57, 751–762 (2010)PubMedCrossRef
7.
Zurück zum Zitat T. Yamanouchi, Y. Tachibana, H. Akanuma, S. Minoda, T. Shinohara, H. Moromizato, H. Miyashita, I. Akaoka, Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am. J. Physiol. 263, E268–E273 (1992)PubMed T. Yamanouchi, Y. Tachibana, H. Akanuma, S. Minoda, T. Shinohara, H. Moromizato, H. Miyashita, I. Akaoka, Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body. Am. J. Physiol. 263, E268–E273 (1992)PubMed
8.
Zurück zum Zitat T. Yamanouchi, Y. Akanuma, Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res. Clin. Pract. 24, S261–S268 (1994)PubMedCrossRef T. Yamanouchi, Y. Akanuma, Serum 1,5-anhydroglucitol (1,5 AG): new clinical marker for glycemic control. Diabetes Res. Clin. Pract. 24, S261–S268 (1994)PubMedCrossRef
9.
Zurück zum Zitat M. Kishimoto, Y. Yamasaki, M. Kubota, K. Arai, T. Morishima, R. Kawamori, T. Kamada, 1,5-Anhydro-d-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18, 1156–1159 (1995)PubMedCrossRef M. Kishimoto, Y. Yamasaki, M. Kubota, K. Arai, T. Morishima, R. Kawamori, T. Kamada, 1,5-Anhydro-d-glucitol evaluates daily glycemic excursions in well-controlled NIDDM. Diabetes Care 18, 1156–1159 (1995)PubMedCrossRef
10.
Zurück zum Zitat J.B. Buse, J.L. Freeman, S.V. Edelman, L. Jovanovic, J.B. McGill, Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 5, 355–363 (2003)PubMedCrossRef J.B. Buse, J.L. Freeman, S.V. Edelman, L. Jovanovic, J.B. McGill, Serum 1,5-anhydroglucitol (GlycoMark): a short-term glycemic marker. Diabetes Technol Ther 5, 355–363 (2003)PubMedCrossRef
11.
Zurück zum Zitat M. Dworacka, H. Winiarska, M. Szymanska, S. Kuczynski, K. Szczawinska, B. Wierusz-Wysocka, 1,5-anhydro-D-glucitol: a novel marker of glucose excursions. Int J Clin Pract Suppl 129, 40–44 (2002)PubMed M. Dworacka, H. Winiarska, M. Szymanska, S. Kuczynski, K. Szczawinska, B. Wierusz-Wysocka, 1,5-anhydro-D-glucitol: a novel marker of glucose excursions. Int J Clin Pract Suppl 129, 40–44 (2002)PubMed
12.
Zurück zum Zitat K.M. Dungan, J.B. Buse, J. Largay, M.M. Kelly, E.A. Button, S. Kato, S. Wittlin, 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29, 1214–1219 (2006)PubMedCrossRef K.M. Dungan, J.B. Buse, J. Largay, M.M. Kelly, E.A. Button, S. Kato, S. Wittlin, 1,5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29, 1214–1219 (2006)PubMedCrossRef
13.
Zurück zum Zitat S.N. Mehta, N. Schwartz, J.R. Wood, B.M. Svoren, L.M. Laffel, Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. Pediatr Diabetes 13, 278–284 (2012)PubMedCrossRef S.N. Mehta, N. Schwartz, J.R. Wood, B.M. Svoren, L.M. Laffel, Evaluation of 1,5-anhydroglucitol, hemoglobin A1c, and glucose levels in youth and young adults with type 1 diabetes and healthy controls. Pediatr Diabetes 13, 278–284 (2012)PubMedCrossRef
14.
Zurück zum Zitat M.J. Kim, H.S. Jung, Y. Hwang-Bo, S.W. Cho, H.C. Jang, S.Y. Kim, K.S. Park, Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol. (2011). doi:10.1007/s00592-011-0302-0 M.J. Kim, H.S. Jung, Y. Hwang-Bo, S.W. Cho, H.C. Jang, S.Y. Kim, K.S. Park, Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol. (2011). doi:10.​1007/​s00592-011-0302-0
15.
Zurück zum Zitat M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Habitual intake of dairy products influences serum 1,5-anhydroglucitol levels independently of plasma glucose. Diabetes Res. Clin. Pract. 90, 122–125 (2010)PubMedCrossRef M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Habitual intake of dairy products influences serum 1,5-anhydroglucitol levels independently of plasma glucose. Diabetes Res. Clin. Pract. 90, 122–125 (2010)PubMedCrossRef
16.
Zurück zum Zitat J.K. Kirk, L.V. Passmore, R.A. Bell, K.M. Narayan, R.B. D’Agostino Jr, T.A. Arcury, S.A. Quandt, Disparities in A1C levels between Hispanics and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 31, 240–246 (2008)PubMedCrossRef J.K. Kirk, L.V. Passmore, R.A. Bell, K.M. Narayan, R.B. D’Agostino Jr, T.A. Arcury, S.A. Quandt, Disparities in A1C levels between Hispanics and non-Hispanic white adults with diabetes: a meta-analysis. Diabetes Care 31, 240–246 (2008)PubMedCrossRef
17.
Zurück zum Zitat A.F. Brown, E.W. Gregg, M.R. Stevens, A.J. Karter, M. Weinberger, M.M. Safford, T.L. Gary, D.A. Caputo, B. Waitzfelder, C. Kim, G.L. Beckles, Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the Translating Research into Action for Diabetes (TRIAD) Study. Diabetes Care 28, 2864–2870 (2005)PubMedCrossRef A.F. Brown, E.W. Gregg, M.R. Stevens, A.J. Karter, M. Weinberger, M.M. Safford, T.L. Gary, D.A. Caputo, B. Waitzfelder, C. Kim, G.L. Beckles, Race, ethnicity, socioeconomic position, and quality of care for adults with diabetes enrolled in managed care: the Translating Research into Action for Diabetes (TRIAD) Study. Diabetes Care 28, 2864–2870 (2005)PubMedCrossRef
18.
Zurück zum Zitat W.H. Herman, K.M. Dungan, B.H. Wolffenbuttel, J.B. Buse, J.L. Fahrbach, H. Jiang, S. Martin, Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 1689–1694 (2009)PubMedCrossRef W.H. Herman, K.M. Dungan, B.H. Wolffenbuttel, J.B. Buse, J.L. Fahrbach, H. Jiang, S. Martin, Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 1689–1694 (2009)PubMedCrossRef
19.
Zurück zum Zitat A.S. Januszewski, C. Karschimkus, K.E. Davis, D. O’Neal, G. Ward, A.J. Jenkins, Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Res. Clin. Pract. 95, e17–e19 (2012)PubMedCrossRef A.S. Januszewski, C. Karschimkus, K.E. Davis, D. O’Neal, G. Ward, A.J. Jenkins, Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects. Diabetes Res. Clin. Pract. 95, e17–e19 (2012)PubMedCrossRef
20.
Zurück zum Zitat M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Y. Moriwaki, T. Yamamoto, Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system. Clin. Chim. Acta 410, 70–73 (2009)PubMedCrossRef M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, Y. Moriwaki, T. Yamamoto, Close relationship between serum concentrations of 1,5-anhydroglucitol and uric acid in non-diabetic male subjects implies common renal transport system. Clin. Chim. Acta 410, 70–73 (2009)PubMedCrossRef
21.
Zurück zum Zitat M. Koga, J. Murai, H. Saito, M. Mukai, D. Toya, N. Tanaka, H. Kanehara, Y. Bando, S. Kasayama, 1,5-Anhydroglucitol levels are low irrespective of plasma glucose levels in patients with chronic liver disease. Ann. Clin. Biochem. 48, 121–125 (2011)PubMedCrossRef M. Koga, J. Murai, H. Saito, M. Mukai, D. Toya, N. Tanaka, H. Kanehara, Y. Bando, S. Kasayama, 1,5-Anhydroglucitol levels are low irrespective of plasma glucose levels in patients with chronic liver disease. Ann. Clin. Biochem. 48, 121–125 (2011)PubMedCrossRef
23.
Zurück zum Zitat K.E. Kinnaird, T.J. Sauerwein, Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis. Endocr Pract 16, 167–170 (2010)PubMedCrossRef K.E. Kinnaird, T.J. Sauerwein, Lack of correlation between 1,5-anhydroglucitol assay and oral glucose tolerance test in patients with cystic fibrosis. Endocr Pract 16, 167–170 (2010)PubMedCrossRef
24.
Zurück zum Zitat T. Yamanouchi, T. Shinohara, N. Ogata, Y. Tachibana, I. Akaoka, H. Miyashita, Common reabsorption system of 1,5-anhydro-d-glucitol, fructose, and mannose in rat renal tubule. Biochim. Biophys. Acta 1291, 89–95 (1996)PubMedCrossRef T. Yamanouchi, T. Shinohara, N. Ogata, Y. Tachibana, I. Akaoka, H. Miyashita, Common reabsorption system of 1,5-anhydro-d-glucitol, fructose, and mannose in rat renal tubule. Biochim. Biophys. Acta 1291, 89–95 (1996)PubMedCrossRef
25.
Zurück zum Zitat S. Tazawa, T. Yamato, H. Fujikura, M. Hiratochi, F. Itoh, M. Tomae, Y. Takemura, H. Maruyama, T. Sugiyama, A. Wakamatsu, T. Isogai, M. Isaji, SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-d-glucitol, and fructose. Life Sci. 76, 1039–1050 (2005)PubMedCrossRef S. Tazawa, T. Yamato, H. Fujikura, M. Hiratochi, F. Itoh, M. Tomae, Y. Takemura, H. Maruyama, T. Sugiyama, A. Wakamatsu, T. Isogai, M. Isaji, SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-d-glucitol, and fructose. Life Sci. 76, 1039–1050 (2005)PubMedCrossRef
26.
Zurück zum Zitat H.S. Freitas, G.F. Anhe, K.F. Melo, M.M. Okamoto, M. Oliveira-Souza, S. Bordin, U.F. Machado, Na-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1 expression and activity. Endocrinology 149, 717–724 (2008)PubMedCrossRef H.S. Freitas, G.F. Anhe, K.F. Melo, M.M. Okamoto, M. Oliveira-Souza, S. Bordin, U.F. Machado, Na-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1 expression and activity. Endocrinology 149, 717–724 (2008)PubMedCrossRef
27.
Zurück zum Zitat H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, J. Brown, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin dependent diabetes. Diabetes 54, 3427–3434 (2005)PubMedCrossRef H. Rahmoune, P.W. Thompson, J.M. Ward, C.D. Smith, G. Hong, J. Brown, Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin dependent diabetes. Diabetes 54, 3427–3434 (2005)PubMedCrossRef
28.
Zurück zum Zitat N. Nakamura, S. Masuda, K. Takahashi, H. Saito, M. Okuda, K. Inui, Decreased expression of glucose and peptide transporters in rat remnant kidney. Drug Metab. Pharmacokinet. 19, 41–47 (2004)PubMedCrossRef N. Nakamura, S. Masuda, K. Takahashi, H. Saito, M. Okuda, K. Inui, Decreased expression of glucose and peptide transporters in rat remnant kidney. Drug Metab. Pharmacokinet. 19, 41–47 (2004)PubMedCrossRef
29.
Zurück zum Zitat H. Shimizu, A. Shouzu, M. Nishikawa, S. Omoto, T. Hayakawa, Y. Miyake, T. Yonemoto, M. Inada, Serum concentration and renal handling of 1,5-anhydro-d-glucitol in patients with chronic renal failure. Ann. Clin. Biochem. 36, 749–754 (1999)PubMed H. Shimizu, A. Shouzu, M. Nishikawa, S. Omoto, T. Hayakawa, Y. Miyake, T. Yonemoto, M. Inada, Serum concentration and renal handling of 1,5-anhydro-d-glucitol in patients with chronic renal failure. Ann. Clin. Biochem. 36, 749–754 (1999)PubMed
30.
Zurück zum Zitat T. Niwa, L. Dewald, J. Sone, T. Miyazaki, M. Kajita, Quantification of serum 1,5-anhydroglucitol in uremic and diabetic patients by liquid chromatography/mass spectrometry. Clin. Chem. 40, 260–264 (1994)PubMed T. Niwa, L. Dewald, J. Sone, T. Miyazaki, M. Kajita, Quantification of serum 1,5-anhydroglucitol in uremic and diabetic patients by liquid chromatography/mass spectrometry. Clin. Chem. 40, 260–264 (1994)PubMed
31.
Zurück zum Zitat H. Yamada, A. Hishida, A. Kato, T. Yoneyama, 1,5-Anhydroglucitol as a marker for the differential diagnosis of acute and chronic renal failure. Nephron 73, 707–709 (1996)PubMedCrossRef H. Yamada, A. Hishida, A. Kato, T. Yoneyama, 1,5-Anhydroglucitol as a marker for the differential diagnosis of acute and chronic renal failure. Nephron 73, 707–709 (1996)PubMedCrossRef
32.
Zurück zum Zitat W.J. Kim, C.Y. Park, K.B. Lee, S.E. Park, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Park, Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care 35, 281–286 (2012)PubMedCrossRef W.J. Kim, C.Y. Park, K.B. Lee, S.E. Park, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Park, Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care 35, 281–286 (2012)PubMedCrossRef
33.
Zurück zum Zitat J.B. McGill, T.G. Cole, W. Nowatzke, S. Houghton, E.B. Ammirati, T. Gautille, M.J. Sarno, 1,5-Anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27, 1859–1865 (2004)PubMedCrossRef J.B. McGill, T.G. Cole, W. Nowatzke, S. Houghton, E.B. Ammirati, T. Gautille, M.J. Sarno, 1,5-Anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27, 1859–1865 (2004)PubMedCrossRef
34.
Zurück zum Zitat K.M. Dungan, J.B. Buse, W.H. Herman, R.F. Arakaki, H.H. Jiang, J.G. Jacobson, J.L. Fahrbach, Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. Diabetes Res. Clin. Pract. 96, e66–e69 (2012)PubMedCrossRef K.M. Dungan, J.B. Buse, W.H. Herman, R.F. Arakaki, H.H. Jiang, J.G. Jacobson, J.L. Fahrbach, Potential for use of 1,5-anhydroglucitol when initiating insulin therapy in people with type 2 diabetes and suboptimal control with oral antidiabetic drugs. Diabetes Res. Clin. Pract. 96, e66–e69 (2012)PubMedCrossRef
35.
Zurück zum Zitat L. Liu, X. Wan, J. Liu, Z. Huang, X. Cao, Y. Li, Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technol. Ther. (2012). doi:10.1089/dia.2012.0055 L. Liu, X. Wan, J. Liu, Z. Huang, X. Cao, Y. Li, Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy. Diabetes Technol. Ther. (2012). doi:10.​1089/​dia.​2012.​0055
36.
Zurück zum Zitat I. Kawasaki, T. Sato, M. Hosoi, K. Yoshioka, T. Yamakita, M. Fukumoto, N. Tanaka, H. Natsuyama, M. Ueda, S. Fujii, Serum 1,5-anhydroglucitol is a strong predictor of the postprandial hyperglycemia in Type 2 diabetes patients (Abstract). Diabetes 54, A76 (2005) I. Kawasaki, T. Sato, M. Hosoi, K. Yoshioka, T. Yamakita, M. Fukumoto, N. Tanaka, H. Natsuyama, M. Ueda, S. Fujii, Serum 1,5-anhydroglucitol is a strong predictor of the postprandial hyperglycemia in Type 2 diabetes patients (Abstract). Diabetes 54, A76 (2005)
37.
Zurück zum Zitat J.C. Won, C.Y. Park, H.S. Park, J.H. Kim, E.S. Choi, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Kim, S.W. Park, 1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Res. Clin. Pract. 84, 51–57 (2009)PubMedCrossRef J.C. Won, C.Y. Park, H.S. Park, J.H. Kim, E.S. Choi, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Kim, S.W. Park, 1,5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Res. Clin. Pract. 84, 51–57 (2009)PubMedCrossRef
38.
Zurück zum Zitat M. Dworacka, H. Winiarska, The application of plasma 1,5-anhydro-d-glucitol for monitoring type 2 diabetic patients. Dis. Markers 21, 127–132 (2005)PubMed M. Dworacka, H. Winiarska, The application of plasma 1,5-anhydro-d-glucitol for monitoring type 2 diabetic patients. Dis. Markers 21, 127–132 (2005)PubMed
39.
Zurück zum Zitat J. Sun, J.T. Dou, X.L. Wang, G.Q. Yang, Z.H. Lü, H. Zheng, F.L. Ma, J.M. Lu, Y.M. Mu, Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin. Med. J. (Engl) 124, 3641–3645 (2011) J. Sun, J.T. Dou, X.L. Wang, G.Q. Yang, Z.H. Lü, H. Zheng, F.L. Ma, J.M. Lu, Y.M. Mu, Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin. Med. J. (Engl) 124, 3641–3645 (2011)
40.
Zurück zum Zitat Y. Wang, Y.L. Zhang, Y.P. Wang, C.H. Lei, Z.L. Sun, A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycemic excursions as measured by continuous glucose monitoring system among type 2 diabetes in a Chinese population. Diabetes Metab. Res. Rev. 28, 357–362 (2012)PubMedCrossRef Y. Wang, Y.L. Zhang, Y.P. Wang, C.H. Lei, Z.L. Sun, A study on the association of serum 1,5-anhydroglucitol levels and the hyperglycemic excursions as measured by continuous glucose monitoring system among type 2 diabetes in a Chinese population. Diabetes Metab. Res. Rev. 28, 357–362 (2012)PubMedCrossRef
41.
Zurück zum Zitat M. Kishimoto, M. Noda, A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc. Diabetol. 22, 115 (2011) M. Kishimoto, M. Noda, A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers. Cardiovasc. Diabetol. 22, 115 (2011)
42.
Zurück zum Zitat T. Yamanouchi, Y. Akanuma, T. Toyota, T. Kuzuya, T. Kawai, S. Kawazu, S. Yoshioka, Y. Kanazawa, M. Ohta, S. Baba, K. Kosaka, Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes 40, 52–57 (1991)PubMedCrossRef T. Yamanouchi, Y. Akanuma, T. Toyota, T. Kuzuya, T. Kawai, S. Kawazu, S. Yoshioka, Y. Kanazawa, M. Ohta, S. Baba, K. Kosaka, Comparison of 1,5-anhydroglucitol, HbA1c, and fructosamine for detection of diabetes mellitus. Diabetes 40, 52–57 (1991)PubMedCrossRef
43.
Zurück zum Zitat S. Tsukui, I. Kobayashi, Effects of age and obesity on glycated haemoglobin and 1,5-anhydroglucitol in screening for type 2 diabetes mellitus. Diabet. Med. 12, 899–903 (1995)PubMedCrossRef S. Tsukui, I. Kobayashi, Effects of age and obesity on glycated haemoglobin and 1,5-anhydroglucitol in screening for type 2 diabetes mellitus. Diabet. Med. 12, 899–903 (1995)PubMedCrossRef
44.
Zurück zum Zitat M. Goto, R. Yamamoto-Honda, T. Shimbo, A. Goto, Y. Terauchi, Y. Kanazawa, M. Noda, Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. Endocr. J. 58, 13–17 (2011)PubMedCrossRef M. Goto, R. Yamamoto-Honda, T. Shimbo, A. Goto, Y. Terauchi, Y. Kanazawa, M. Noda, Correlation between baseline serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during oral glucose tolerance tests. Endocr. J. 58, 13–17 (2011)PubMedCrossRef
45.
Zurück zum Zitat D.A. Robertson, K.G. Alberti, G.K. Dowse, P. Zimmet, J. Tuomilehto, H. Gareeboo, Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? The Mauritius Noncommunicable Diseases Study Group. Diabet. Med. 10, 56–60 (1993)PubMedCrossRef D.A. Robertson, K.G. Alberti, G.K. Dowse, P. Zimmet, J. Tuomilehto, H. Gareeboo, Is serum anhydroglucitol an alternative to the oral glucose tolerance test for diabetes screening? The Mauritius Noncommunicable Diseases Study Group. Diabet. Med. 10, 56–60 (1993)PubMedCrossRef
46.
Zurück zum Zitat T.M. Nguyen, L.M. Rodriguez, K.J. Mason, R.A. Heptulla, Serum 1,5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. Pediatr Diabetes 8, 214–219 (2007)PubMedCrossRef T.M. Nguyen, L.M. Rodriguez, K.J. Mason, R.A. Heptulla, Serum 1,5-anhydroglucitol (Glycomark) levels in children with and without type 1 diabetes mellitus. Pediatr Diabetes 8, 214–219 (2007)PubMedCrossRef
47.
Zurück zum Zitat A.C. Moses, P. Raskin, N. Khutoryansky, Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. Diabet. Med. 25, 200–205 (2008)PubMedCrossRef A.C. Moses, P. Raskin, N. Khutoryansky, Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. Diabet. Med. 25, 200–205 (2008)PubMedCrossRef
48.
Zurück zum Zitat R. Beck, M. Steffes, D. Xing, K. Ruedy, N. Mauras, D.M. Wilson, C. Kollman, Diabetes Research in Children Network (DirecNet) Study Group, The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. Pediatr Diabetes 12, 690–695 (2011)PubMedCrossRef R. Beck, M. Steffes, D. Xing, K. Ruedy, N. Mauras, D.M. Wilson, C. Kollman, Diabetes Research in Children Network (DirecNet) Study Group, The interrelationships of glycemic control measures: HbA1c, glycated albumin, fructosamine, 1,5-anhydroglucitrol, and continuous glucose monitoring. Pediatr Diabetes 12, 690–695 (2011)PubMedCrossRef
49.
Zurück zum Zitat M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, A. Imagawa, T. Hanafusa, Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes. Clin. Biochem. 43, 1265–1267 (2010)PubMedCrossRef M. Koga, J. Murai, H. Saito, M. Mukai, S. Kasayama, A. Imagawa, T. Hanafusa, Serum 1,5-anhydroglucitol levels in patients with fulminant type 1 diabetes are lower than those in patients with type 2 diabetes. Clin. Biochem. 43, 1265–1267 (2010)PubMedCrossRef
50.
Zurück zum Zitat M. Pontoglio, D. Prié, C. Cheret, A. Doyen, C. Leroy, P. Froguel, G. Velho, M. Yaniv, G. Friedlander, HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 1, 359–365 (2000)PubMedCrossRef M. Pontoglio, D. Prié, C. Cheret, A. Doyen, C. Leroy, P. Froguel, G. Velho, M. Yaniv, G. Friedlander, HNF1alpha controls renal glucose reabsorption in mouse and man. EMBO Rep. 1, 359–365 (2000)PubMedCrossRef
51.
Zurück zum Zitat A. Pal, A.J. Farmer, C. Dudley, M.P. Selwood, B.A. Barrow, R. Klyne, J.P. Grew, M.I. McCarthy, A.L. Gloyn, K.R. Owen, Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 33, 252–257 (2010)PubMedCrossRef A. Pal, A.J. Farmer, C. Dudley, M.P. Selwood, B.A. Barrow, R. Klyne, J.P. Grew, M.I. McCarthy, A.L. Gloyn, K.R. Owen, Evaluation of serum 1,5 anhydroglucitol levels as a clinical test to differentiate subtypes of diabetes. Diabetes Care 33, 252–257 (2010)PubMedCrossRef
52.
Zurück zum Zitat J. Skupien, S. Gorczynska-Kosiorz, T. Klupa, K. Wanic, E.A. Button, J. Sieradzki, M.T. Malecki, Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. Diabetes Care 31, 1496–1501 (2008)PubMedCrossRef J. Skupien, S. Gorczynska-Kosiorz, T. Klupa, K. Wanic, E.A. Button, J. Sieradzki, M.T. Malecki, Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1alpha maturity-onset diabetes of the young. Diabetes Care 31, 1496–1501 (2008)PubMedCrossRef
53.
Zurück zum Zitat W.J. Kim, C.Y. Park, S.E. Park, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Park, S.W. Kim, H.S. Park, Y.J. Kim, S.J. Song, H.Y. Ahn, Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. Diabet. Med. (2012). doi:10.1111/j.1464-5491.2012.03613.x W.J. Kim, C.Y. Park, S.E. Park, E.J. Rhee, W.Y. Lee, K.W. Oh, S.W. Park, S.W. Kim, H.S. Park, Y.J. Kim, S.J. Song, H.Y. Ahn, Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. Diabet. Med. (2012). doi:10.​1111/​j.​1464-5491.​2012.​03613.​x
54.
Zurück zum Zitat E. Selvin, L.M. Francis, C.M. Ballantyne, R.C. Hoogeveen, J. Coresh, F.L. Brancati, M.W. Steffes, Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 34, 960–967 (2011)PubMedCrossRef E. Selvin, L.M. Francis, C.M. Ballantyne, R.C. Hoogeveen, J. Coresh, F.L. Brancati, M.W. Steffes, Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 34, 960–967 (2011)PubMedCrossRef
55.
Zurück zum Zitat R.A. Kowluru, Q. Zhong, M. Kanwar, Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp. Eye Res. 90, 617–623 (2010)PubMedCrossRef R.A. Kowluru, Q. Zhong, M. Kanwar, Metabolic memory and diabetic retinopathy: role of inflammatory mediators in retinal pericytes. Exp. Eye Res. 90, 617–623 (2010)PubMedCrossRef
56.
Zurück zum Zitat W. Li, X. Liu, M. Yanoff, S. Cohen, X. Ye, Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia 39, 537–547 (1996)PubMedCrossRef W. Li, X. Liu, M. Yanoff, S. Cohen, X. Ye, Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia 39, 537–547 (1996)PubMedCrossRef
57.
Zurück zum Zitat M. Dworacka, H. Winiarska, M. Borowska, M. Abramczyk, T. Bobkiewicz-Kozlowska, G. Dworacki, Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. Circ. J. 71, 962–967 (2007)PubMedCrossRef M. Dworacka, H. Winiarska, M. Borowska, M. Abramczyk, T. Bobkiewicz-Kozlowska, G. Dworacki, Pro-atherogenic alterations in T-lymphocyte subpopulations related to acute hyperglycaemia in type 2 diabetic patients. Circ. J. 71, 962–967 (2007)PubMedCrossRef
58.
Zurück zum Zitat M. Ohira, K. Endo, T. Oyama, T. Yamaguchi, N. Ban, H. Kawana, D. Nagayama, A. Nagumo, A. Saiki, T. Murano, H. Watanabe, Y. Miyashita, K. Shirai, Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 60, 78–85 (2011)PubMedCrossRef M. Ohira, K. Endo, T. Oyama, T. Yamaguchi, N. Ban, H. Kawana, D. Nagayama, A. Nagumo, A. Saiki, T. Murano, H. Watanabe, Y. Miyashita, K. Shirai, Improvement of postprandial hyperglycemia and arterial stiffness upon switching from premixed human insulin 30/70 to biphasic insulin aspart 30/70. Metabolism 60, 78–85 (2011)PubMedCrossRef
59.
Zurück zum Zitat M. Watanabe, Y. Kokubo, A. Higashiyama, Y. Ono, Y. Miyamoto, T. Okamura, Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 216, 477–483 (2011)PubMedCrossRef M. Watanabe, Y. Kokubo, A. Higashiyama, Y. Ono, Y. Miyamoto, T. Okamura, Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 216, 477–483 (2011)PubMedCrossRef
Metadaten
Titel
1,5-Anhydroglucitol in diabetes mellitus
verfasst von
Won Jun Kim
Cheol-Young Park
Publikationsdatum
01.02.2013
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 1/2013
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9760-6

Weitere Artikel der Ausgabe 1/2013

Endocrine 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.